Phase II Results of Sacituzumab Tirumotecan (sac-TMT) plus Pembrolizumab in Advanced Urothelial Carcinoma Presented at 2026 ESMO
Sichuan Kelun-Biotech announced that updated results from the Phase II MK-2870-002/SKB264-II-06 study were presented at the 2026 ESMO Congress in Madrid. The study covers sacituzumab tirumotecan, also known as SKB264/MK-2870 and 佳泰莱, combined with MSD's anti-PD-1 therapy in advanced urothelial carcinoma. The company's announcement was dated Oct. 24, 2026, and issued from Chengdu, China.
CHENGDU, China, Oct. 24, 2026 /PRNewswire/ — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (“Kelun-Biotech” or the “Company”, 6990.HK) announced that at the 2026 European Society for Medical Oncology (ESMO) Congress held in Madrid, updated results from the Phase II MK-2870-002/SKB264-II-06 study of sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870)(佳泰莱®) plus MSD’s[1] anti-programmed cell death protein 1 […]